Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Surveying Stigma: MAFLD’s Nomenclature from Patient and Provider Perspectives

Authors: Younossi ZM et al.
Published in Journal of Hepatology (November 2023)
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 38% of adults worldwide, a statistic which is expected to increase with the rise of type 2 diabetes and obesity.
Read MoreSurveying Stigma: MAFLD’s Nomenclature from Patient and Provider Perspectives

Cardiovascular Disease in MASLD Patients: Mitigating Risks

Authors: Mellemkjær A et al.
Published in European Journal of Internal Medicine (November 2023)
The term metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as an alternative to non-alcoholic fatty liver disease (NAFLD)’s exclusionary nomenclature.
Read MoreCardiovascular Disease in MASLD Patients: Mitigating Risks

Exploring the Promise of Pan-PPAR Agonism

Authors: Staels B, Butruille L, and Francque S
Published in Journal of Hepatology (November 2023)
Peroxisome proliferated-activated receptors (PPARs), including α, β/δ and γ isotypes, are a nuclear receptor family of lipid sensors activated by natural fatty acid derivatives and pharmacological agonists.
Read MoreExploring the Promise of Pan-PPAR Agonism

Advancing Fibrosis Imaging: An Evaluation of Radiotracer Efficacy

Authors: Eriksson O and Velikyan I
Published in Pharmaceuticals (November 2023)
Tissue fibrosis is induced by an excessive collagen deposition in organs suffering from inflammation and is associated with several diseases, including non-alcoholic steatohepatitis (NASH).
Read MoreAdvancing Fibrosis Imaging: An Evaluation of Radiotracer Efficacy

Global research on fatty liver disease: a review

Authors: Lazarus JV, Mark HE, Allen AM, et al.
Published in J Hepatol (September 2023)
In this study, a large, global, multidisciplinary panel discussed priorities within the field of fatty liver disease, including its burden, policies surrounding the issue and treatment options.
Read MoreGlobal research on fatty liver disease: a review

Managing Hepatocellular Carcinoma in NAFLD: a review

Authors: Cadar R, Lupascu Ursulescu C, Vasilescu AM, et al
Published in Life (Basel) (September 2023)
Currently, there are rising levels of non-alcoholic fatty liver disease (NAFLD). With this, comes a concurrent increase in hepatocellular carcinoma (HCC) cases.
Read MoreManaging Hepatocellular Carcinoma in NAFLD: a review

The new paradigm of cardiometabolic syndrome: a review

Authors: Khan AR, Salama AH, Aleem Z, et al.
Published in Cureus (September 2023)
Cardiometabolic syndrome (CMS) involves a complex interplay of many issues, involving obesity, metabolic dysregulation, cardiovascular disease, insulin resistance and more. This condition extends to clinical implications including non-alcoholic fatty liver disease (NAFLD) as well as cancer and sleep apnoea.
Read MoreThe new paradigm of cardiometabolic syndrome: a review

Machine Learning Models for the Detection of (At-Risk) NASH: Unravelling the Potential

Authors: Lee J, Westphal M, Vali Y et al.
Published in Hepatology (July 2023)
Despite its health complications and inherent intra- and inter-observer variability, liver biopsy remains the gold standard for the detection of non-alcoholic steatohepatitis (NASH).
Read MoreMachine Learning Models for the Detection of (At-Risk) NASH: Unravelling the Potential

Discerning sex-related differences in NAFLD patients via metabolic profiling

Authors: Fotakis C, Kalafi IP, Amanitidou AI et al.
Published in Frontiers in Endocrinology (October 2023)
Research into personalised medicine for non-alcoholic fatty liver disease (NAFLD) underscores the importance of acknowledging NAFLD patients’ unique clinical phenotypes when developing targeted pharmacotherapies.
Read MoreDiscerning sex-related differences in NAFLD patients via metabolic profiling

Multiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion: Differential MAFLD Risks in Patients With Type 1 Diabetes?

Authors: Csermely A, Mantovani A, Morieri ML et al.
Published in Diabetes & Metabolism (September 2023)
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), affects 30% of adults worldwide and up to 40% of those with type 1 diabetes mellitus (T1DM)
Read MoreMultiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion: Differential MAFLD Risks in Patients With Type 1 Diabetes?

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES